The identification of the FIP1L1- PDGFRA fusion gene is significant since imatinib has excellent efficacy at low doses (100-400 mg daily) in FIP1L1-PDGFRA-positive neoplasms [2,5]. The gene discussed is PDGFRA; the disease is neoplasm.